Subcutaneous infliximab for inflammatory bowel disease: Clinical evidence, pharmacokinetics, and implementation challenges

Authors

• Mir Zulqarnain, Cedars-Sinai Medical Center
• Parakkal Deepak, Washington University School of Medicine in St. Louis
• Andres J. Yarur, Cedars-Sinai Medical Center

Journal

Therapeutic Advances in Gastroenterology

Publication Date

2026

Volume

19

Document Type

Open Access Publication

DOI

10.1177/17562848261491027

Rights and Permissions

Zulqarnain M, Deepak P, Yarur AJ. Subcutaneous infliximab for inflammatory bowel disease: Clinical evidence, pharmacokinetics, and implementation challenges. Therapeutic Advances in Gastroenterology. 2026;19. doi:10.1177/17562848261491027. © The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Recommended Citation

Zulqarnain, Mir; Deepak, Parakkal; and Yarur, Andres J., "Subcutaneous infliximab for inflammatory bowel disease: Clinical evidence, pharmacokinetics, and implementation challenges." Therapeutic Advances in Gastroenterology. 19, (2026).
https://digitalcommons.wustl.edu/oa_4/7680

Department

ICTS (Institute of Clinical and Translational Sciences)